CANTOS Ushers in a New Calculus of Inflammasome Targeting for Vascular Protection-and Maybe More.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 29056511.
- Also identified by DOI 10.1016/j.cmet.2017.09.022.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Despite overwhelming basic science linking inflammation to the pathobiology of atherothrombosis, the specific clinical evidence indicating cardiovascular benefits from anti-inflammatory pharmacotherapy has been lacking. The CANTOS trial (Ridker et al., 2017a) now provides the first largescale proof of concept that inflammasome targeting can reduce cardiovascular events-and, surprisingly, lung cancer.
Medical subject headings
- Atherosclerosis
- Calculi